Cas No. |
Product name |
344458-19-1 |
PJ34 |
more... |
PJ-34 is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2. |
344458-15-7 |
PJ34(HCL) |
more... |
PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2. |
868540-17-4 |
Carfilzomib(PR171) |
more... |
Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 su... |
459868-92-9 |
Rucaparib(AG-014699) |
more... |
Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to eight other PARP domains. Phase 3. |
133407-82-6 |
MG132 |
more... |
MG-132 is an inhibitor of proteasome with IC50 of 100 nM, and also inhibits calpain with IC50 of 1.2 μM. |
912444-00-9 |
Veliparib (ABT-888) |
more... |
Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively. It is inactive to SIRT2. Phase 3. |
763113-22-0 |
Olaparib (AZD2281, KU0059436) |
more... |
Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM, 300-times less effective against tankyrase-1. Phase 3. |
1207456-01-6 |
BMN673 |
more... |
BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3. |
934162-61-5 |
A-966492 |
more... |
A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively. |
1072833-77-2 |
MLN2238 |
more... |
MLN2238(Ixazomib) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. |